Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders

Neurobiology of Aging

Volumn 32, Issue 12, 2011, Pages 2131-2141

  Glodzik, Lidia ^a   de Santi, Susan ^a,b   Tsui, Wai Hon ^a,c   Mosconi, Lisa ^a   Zinkowski, Raymond ^d   Pirraglia, Elizabeth ^a   Wang, Hui Yu ^a,e   Li, Yi ^a   Rich, Kenneth E ^a   Zetterberg, Henrik ^f   Blennow, Kaj ^f   Mehta, Pankaj ^g   de Leon, Mony J ^a,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MedAvante Inc   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d Applied NeuroSolutions Inc   (United States)

^e SHANDONG UNIVERSITY   (China)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Aging; Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Medial temporal lobe; Memory performance; Phosphorylated tau 231; Prediction

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; TAU 231 PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GERIATRIC PATIENT; GRAY MATTER; HUMAN; IMAGE ANALYSIS; LONGITUDINAL STUDY; LUMBAR PUNCTURE; MALE; MEDIAL TEMPORAL ATROPHY; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEMI STRUCTURED INTERVIEW;

AGED; AGED, 80 AND OVER; ATROPHY; BIOLOGICAL MARKERS; COGNITION DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MEMORY DISORDERS; MIDDLE AGED; PHOSPHORYLATION; TAU PROTEINS; TEMPORAL LOBE;

EID: 79959232075     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.12.026     Document Type: Article

References (44)

1. Ashburner J., Friston K.J. Voxel-based morphometry-the methods. Neuroimage 2000, 11:805-821.
2. Bennet D.A., Schneider J.A., Bienias J.L., Evans D.A., Wilson R.S. Mild cognitive impairment is related to Alzheimer's disease pathology and cerebral infarctions. Neurology 2005, 64:834-841.
3. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet Neurol. 2006, 368:387-403.
4. Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol. Chem. Neuropathol. 1995, 26:231-245.
5. Boyle P.A., Wilson R.S., Aggarwal N.T., Tang Y., Bennett D.A. Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology 2006, 67:441-445.
6. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
7. Brett M., Anton J.C., Valabregue R., Poline J.-B. Region of interest analysis using an SPM toolbox. Neuroimage 16: pp 8th International Conference on Functional Mapping of the Human Brain, June 2-6, 2002 2002.
8. Brys M., Pirraglia E., Rich K., Rolstad S., Mosconi L., Switalski R., Glodzik-Sobanska L., De Santi S., Zinkowski R., Mehta D., Pratico D., Saint Louis L.A., Wallin A., Blennow K., de Leon M.J. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol. Aging 2009, 30:682-690.
9. De Santi S., Pirraglia E., Barr W.B., Babb J., Williams S., Rogers K., Glodzik L., Brys M., Mosconi L., Reisberg B., Ferris S., de Leon M.J. Robust and conventional neuropsychological norms: diagnosis and prediction of age-related cognitive decline. Neuropsychology 2008, 22:469-484.
10. Fagan A.M., Head D., Shah A.R., Marcus D., Mintun M., Morris J.C., Holtzman D.M. Decreased cerebrospinal fluid A42 correlates with brain atrophy in cognitively normal elderly. Ann. Neurol. 2009, 65:176-183.
11. Fagan A.M., Roe C.M., Xiong C., Mintun M., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau/beta-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 2007, 64:343-349.
12. Fischer P., Jungwirth S., Zehetmayer S., Weissgram S., Hoenigschnabl S., Gelpi E., Krampla W., Tragl K.H. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology 2007, 68:288-291.
13. Fitzpatrick A.L., Kuller L.H., Ives D.G., Lopez O.L., Jagust W., Breitner J.C.S., Jones B., Lyketsos C., Dulberg C. Incidence and prevalence of dementia in the cardiovascular health study. JAGS 2004, 52:195-204.
14. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J. Psychiat. Res. 1975, 12:189-198.
15. Freeborough P.A., Woods R.P., Fox N.C. Accurate registration of serial 3D MR brain images and its application to visualizing change in neurodegenerative disorders. J. Comput. Assist. Tomogr. 1996, 20:1012-1022.
16. Gilbert J.G. Guild Memory Test Manual 1970, UNICO National Mental Health Research Center, Newark, NJ.
17. Glodzik-Sobanska L., Rusinek H., Mosconi L., Li Y., Zhan J., De Santi S., Convit A., Rich K.E., Brys M., de Leon M.J. The role of quantitative structural imaging in the early diagnosis of Alzheimer's disease. Neuroimag. Clin. N. Am. 2005, 15:803-826.
18. Golomb J., de Leon M.J., Kluger A., George A.E., Tarshish C., Ferris S.H. Hippocampal atrophy in normal aging an association with recent memory impairment. Arch. Neurol. 1993, 50:967-973.
19. Good C.D., Scahill R.I., Fox N.C., Ashburner J., Friston K.J., Chan D., Crum W.R., Rossor M.N., Frackowiak R.S.J. Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. Neuroimage 2002, 17:29-46.
20. Gustafson D.R., Skoog I., Rosengren L., Zetterberg H., Blennow K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J. Neurol. Neurosurg. Psychiatry 2006, 78:461-464.
21. Jessen F., Feyen L., Freymann K., Tepest R., Maier W., Heun R., Schild H.H., Scheef L. Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiol. Aging 2006, 27:1751-1756.
22. Kluger A., Ferris S.H., Golomb J., Mittelman M.S., Reisberg B. Neuropsychological prediction of decline to dementia in nondemented elderly. J. Geriat. Psychiatry Neurol. 1999, 12:168-179.
23. Kohnken R., Buerger K., Zinkowski R., Miller C., Kerkman D., DeBernardis J., Shen J., Moller H.J., Davies P., Hampel H. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 2000, 287:187-190.
24. Li G., Sokal I., Quinn J.F., Leverenz J.B., Brodey M., Schellenberg G.D., Kaye J.A., Raskind M.A., Zhang J., Peskind E.R., Montine T.J. CSF tau/A{Beta}42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 2007, 69:631-639.
25. Loew A.D., Yanowsky I., Parikshak N., Hua X., Lee S., Toga A.W., Jack C.R.J., Bernstein M.A., Briston P.J., Gunter J.L., Ward C.P., Borowski B.J., Shaw L.M., Trojanowski J.Q., Fleisher A.S., Harvey D., Kornak J., Schuff N., Alexander G.E., Weiner M.W., Thompson P.M. Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage 2009, 45:645-655. Alzheimer's Disease Neuroimaging Initiative.
26. Mehta P.D., Pirttila T., Mehta S.P., Sersen E.A., Aisen P.S., Wisniewski H.M. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch. Neurol. 2000, 57:100-105.
27. Mortimer J.A., Gosche K.M., Riley K.P., Markesbery W.R., Snowdon D.A. Delayed recall hippocampal volume and Alzheimer neuropathology. Findings from the Nun Study. Neurology 2004, 62:428-432.
28. NIH Publication No. 02-5125, 2002. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults (Adult Treatment Panel III). Final Report. Circulation 106, p. 3143.
29. Petersen R.C., Smith G.E., Ivnik R.J., Kokmen E., Tangalos E.G. Memory function in very early Alzheimer's disease. Neurology 1994, 44:867-872.
30. Reisberg B., London E., Ferris S.H., Borenstein J., Scheier L., de Leon M.J. The brief cognitive rating scale: language motoric, and mood concomitants in primary degenerative dementia. Psychopharmacol. Bull. 1983, 19:702-708.
31. Reisberg B., Sclan S.G., Franssen E.H., de Leon M.J., Kluger A., Torossian C.L., Shulman E., Steinberg G., Monteiro I., McRae T., Boksay I., Mackell J.A., Ferris S.H. Clinical stages of normal aging and Alzheimer's disease: the GDS staging system. Neurosci. Res. Commun. 1993, 13(Suppl. 1):551-554.
32. Rusinek H., De Santi S., Frid D., Tsui W., Tarshish C., Convit A., de Leon M.J. Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology 2003, 229:691-696.
33. Rusinek H., Endo Y., De Santi S., Frid D., Tsui W.H., Segal S., Convit A., de Leon M.J. Atrophy rate in medial temporal lobe during progression of Alzheimer disease. Neurology 2004, 63:2354-2359.
34. Saykin A.J., Wishart H.A., Rabin L.A., Santulli R.B., Flashman L.A., West J.D., McHugh T.L., Mamourian A.C. Older adults with cognitive complaints show brain atrophy simialr to that of amnestic MCI. Neurology 2006, 67:834-842.
35. Silbert L.C., Quinn J.F., Moore M.M., Corbridge E., Ball M.J., Murdoch G., Sexton G., Kaye J.A. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 2003, 61:487-492.
36. Skoog I., Davidsson P., Aevarsson O., Vanderstichele H., Vanmechelen E., Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Demen. Geriatr. Cogn. Disord. 2003, 15:169-176.
37. Sluimer, J, Bouwman, F.H., Vrenken, H., Blankenstein, M.A., Barkhof, F., van der Flier, W. M., Scheltens, P., 2008. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol. Aging, in press, 10.1016/j.neurobiolaging.2008.06.016. [Epub ahead of print].
38. Stomrud E., Hansson O., Blennow K., Minthon L., Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Demen. Geriatr. Cogn. Disord. 2007, 24:118-124.
39. Talairach J., Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain 1988, Thieme, Stuttgart.
40. Vemuri P., Wiste H.J., Weigand S.D., Shaw L.M., Trojanowski J.Q., Weiner M.W., Knopman D.S., Petersen R.C., Jack C.R.J.d MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 2009, 73:287-293. on behalf of the Alzheimer's Diasese Neuroimaging Initiative.
41. Wechsler D. Wechsler Adult Intelligence Scale-Revised 1981, Harcourt Brace Jovanovich, New York.
42. Welsh K., Butters N., Hughes J., Mohs R., Heyman A. Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch. Neurol. 1991, 48:278-281.
43. Wiltfang J., Esselmann H., Bibl M., Hull M., Hampel H., Kessler H., Frolich L., Schroder J., Peters O., Jessen F., Luckhaus C., Perneczky R., Jahn H., Fiszer M., Maler J.M., Zimmermann R., Bruckmoser R., Kornhuber J., Lewczuk P. Amyloid beta peptide ratio 42/40 but not A Beta 42 correlates with phospho-tau in patients with low- and high-CSF A Beta 40 load. J. Neurochem. 2007, 101:1053-1059.
44. Zehnder A.E., Blasi S., Berres M., Speigel R., Monsch A.U. Lack of practice effects on neuropsychological tests as early cognitive markers of Alzheimer disease?. Am. J. Alzheimer's Dis. Other Demen. 2007, 22:416-426.